Innoviva (INVA)
Nasdaq Market Closed
Innoviva, Inc. is a healthcare company built around a mix of royalty interests, operating businesses, and strategic investments in pharmaceutical assets. Its best-known economic exposure comes from royalties tied to respiratory medicines commercialised by GlaxoSmithKline, including products in the Ellipta inhaler family such as Breo/Relvar, Anoro, and Trelegy. These therapies are used in the treatment of respiratory conditions including chronic obstructive pulmonary disease and asthma, giving Innoviva a differentiated position among public healthcare companies as a holder of long-duration cash-generating interests rather than a traditional drug developer alone.
Alongside its royalty portfolio, Innoviva has expanded into operating assets focused on critical care and infectious disease. This area includes hospital-oriented medicines and development programmes aimed at serious bacterial and fungal infections, a market shaped by high medical need, antimicrobial resistance, and relatively specialised commercial channels. The company’s strategy combines cash flows from established products with selective ownership of businesses and assets that may benefit from demand for novel anti-infective treatments.
For investors, Innoviva is notable because its financial profile is influenced by both pharmaceutical product performance and capital allocation decisions. Revenue can depend on prescription trends, competitive dynamics, patent protection, regulatory developments, and the commercial execution of partners or subsidiaries. Unlike many biotechnology companies that rely primarily on early-stage research pipelines, Innoviva operates with a portfolio approach, balancing royalty economics with direct participation in healthcare markets where specialised products can address critical patient needs.
Last updated
- Market Cap
- 1.6B
- P/E
- 3.18
- P/FCF
- 8.8
- P/S
- 3.81
- Enterprise Value
- 1.26B
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 1350 OLD BAYSHORE HIGHWAY, BURLINGAME, CA, 94010
3 Bargain-Cheap Small Caps Worth a Second Look
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
10 stocks you can bet on being inflation-proof
FDA approves Innoviva’s bacterial pneumonia treatment
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
Is Innoviva (INVA) Stock Undervalued Right Now?
Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy
Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail
Pfizer (PFE) Gets FDA Acceptance for Braftovi + Mektovi sNDAs
J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits
AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease
Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval
Innoviva (INVA) Gains As Market Dips: What You Should Know
Innoviva (INVA) Stock Moves -1.06%: What You Should Know
Innoviva (INVA) Gains As Market Dips: What You Should Know
Innoviva (INVA) Dips More Than Broader Markets: What You Should Know
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 1.6B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 1.26B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 3.18
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.19
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 3.81
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 6.26
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 2.99
- EPS
- 6.83
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 8.8
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 8.72
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 181.97M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 37.59%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 27.46%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.19
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 21.13
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 20.07
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 16.5
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 782.6K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 21.7
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 97.99M | 114.61M | 107.8M | 100.28M | 88.63M |
| Gross profit | 75.83M | 75.67M | 75.54M | 89.69M | 73.32M |
| Operating income | 38.15M | 38.99M | 34.58M | 48.75M | 41.43M |
| EBITDA | 48.2M | 49.11M | 44.68M | 58.79M | 51.39M |
| Net income | 186.6M | 164.15M | 89.91M | 63.69M | -46.58M |
| Basic EPS | 2.52 | 2.37 | 1.3 | 1.01 | -0.74 |
| Diluted EPS | 2.22 | 1.95 | 1.08 | 0.77 | -0.74 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 1.84B | 1.64B | 1.43B | 1.33B | 1.25B |
| Total liabilities | 494.93M | 462.32M | 419.16M | 618.75M | 607.49M |
| Total equity | 1.34B | 1.17B | 1.01B | 714.82M | 646.91M |
| Cash & equivalents | 603.09M | 550.94M | 476.51M | 397.53M | 319.09M |
| Current assets | 772.62M | 727.52M | 684.57M | 651.78M | 582.02M |
| Current liabilities | 36.56M | 49.7M | 48.47M | 246.56M | 234.75M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 35.28M | 54.51M | 49.73M | 44.07M | 48.62M |
| Investing cash flow | 37.01M | 23.64M | 18.41M | 33.12M | -34.67M |
| Financing cash flow | -20.15M | -3.72M | 10.84M | 1.25M | 183K |
| Change in cash | 52.14M | 74.43M | 78.98M | 78.44M | 14.13M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 3 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| form 3 | Form 3 — Linden Josephine | View Filing | |
| form 4 | Form 4 — Zhen Marianne | View Filing | |
| form 4 | Form 4 — Raifeld Pavel | View Filing | |
| form 4 | Form 4 — Basso Stephen | View Filing | |
| edgar index | 8-K — Innoviva, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Linden Josephine | View Filing | |
| form 4 | Form 4 — Linden Josephine | View Filing | |
| form 4 | Form 4 — Linden Josephine | View Filing | |
| form 4 | Form 4 — Raifeld Pavel | View Filing | |
| form 4 | Form 4 — Basso Stephen | View Filing | |
| edgar index | SCHEDULE 13D/A — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 8-K — Innoviva, Inc. | View Filing | |
| edgar index | 10-Q — Innoviva, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Innoviva, Inc. | View Filing | |
| edgar index | S-8 — Innoviva, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Haimovitz Jules | View Filing | |
| form 4 | Form 4 — Haimovitz Jules | View Filing | |
| form 4 | Form 4 — Small Derek A | View Filing | |
| form 4 | Form 4 — Small Derek A | View Filing | |
| form 4 | Form 4 — Basso Stephen | View Filing | |
| form 4 | Form 4 — Basso Stephen | View Filing | |
| form 4 | Form 4 — Schlesinger Sarah J. | View Filing | |
| form 4 | Form 4 — Schlesinger Sarah J. | View Filing | |
| form 4 | Form 4 — Zhen Marianne | View Filing | |
| form 4 | Form 4 — Zhen Marianne | View Filing | |
| form 4 | Form 4 — Raifeld Pavel | View Filing | |
| form 4 | Form 4 — Raifeld Pavel | View Filing | |
| form 4 | Form 4 — DiPaolo Mark | View Filing | |
| form 4 | Form 4 — DiPaolo Mark | View Filing | |
| edgar index | SCHEDULE 13G — Innoviva, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Innoviva, Inc. | View Filing | |
| edgar index | 10-K/A — Innoviva, Inc. | View Filing | |
| edgar index | DEF 14A — Innoviva, Inc. | View Filing | |
| edgar index | 10-K — Innoviva, Inc. | View Filing | |
| edgar index | 8-K — Innoviva, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| form 4 | Form 4 — Zhen Marianne | View Filing | |
| form 4 | Form 4 — Raifeld Pavel | View Filing | |
| form 4 | Form 4 — Basso Stephen | View Filing | |
| edgar index | SCHEDULE 13G/A — Innoviva, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Innoviva, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| form 4 | Form 4 — Zhen Marianne | View Filing | |
| form 4 | Form 4 — Basso Stephen | View Filing | |
| form 4 | Form 4 — Basso Stephen | View Filing | |
| edgar index | 8-K — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 4 — Innoviva, Inc. | View Filing | |
| edgar index | 10-Q — Innoviva, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Raifeld Pavel | View Filing | |
| form 4 | Form 4 — Basso Stephen | View Filing |